Life Sciences

For over 35 years, lawyers in our Life Sciences practice group have played an instrumental role in the growth of many of the industry's most sophisticated life sciences companies. Our client base includes both public and private companies, based in the U.S. and abroad, and spans the breadth of the life science industry sectors from therapeutics to drug delivery and formulation to medical technology and devices.

We deliver an unparalleled combination of innovative legal expertise, deep industry knowledge and practical understanding of our clients' business needs.

Because of our deep domain expertise we are often called upon to represent venture capital clients in their investments in life sciences companies, as well as the investment banks and lending institutions servicing those companies.

Key Facts

  • Since January 2013, we have handled 46 life sciences U.S. IPOs, more than any other law firm, and completed 63 life sciences follow-on offerings, for a combined total in excess of $8.3 billion
  • Since 2010, we have handled more than 130 life sciences M&A transactions for a combined total deal value in excess of $27 billion
  • In the last four years, our dedicated life science transactions team has completed more than 120 deals valued in excess of $35 billion
  • We have helped life sciences companies raise more than $3 billion in more than 150 financings since 2013

Rankings and Accolades

    "According to industry peers, the licensing, tax and inversion, private investment, capital market and M&A work performed by Cooley is top tier."

    LMG Life Sciences

  • Named "Law Firm of the Year" in Biotechnology by US News – Best Lawyers in 2011, the first year the category was awarded
  • Ranked #1 in issuer-side life sciences IPOs from 2000 to present (Source: IPO Vital Signs)
  • Consistently rank #1 in the BioPharm Insight Biotechnology and Pharmaceutical Licensing League Table Report from 2010 - Q2 2015 
  • Ranked #1 in Life Sciences by Chambers USA: America's Leading Lawyers for Business from 2007-2014
  • Fifteen Cooley transactions have been awarded or nominated for the Allicense "Breakthrough Deal of the Year" since 2000
  • Rank #1 in life sciences venture financings for 2013 and 2014 per VentureSource
  • Ranked as Law Firm of the Year in Life Sciences in the Financial & Transactional and M&A categories by Euromoney's LMG Life Sciences Awards in 2013 and 2014 

Life Science Industry Knowledge

Many of our lawyers have practical business experience, or have earned advanced degrees in relevant life science disciplines

  • 82 lawyers with undergraduate degrees in scientific or clinical fields, including Chemistry, Biology, Mechanical Engineering, Chemical Engineering, Medicine and Nursing
  • 45+ lawyers with Ph.D.s in scientific fields

Our lawyers have deep expertise across all aspects of life sciences technologies:

  • Biologics
  • Biosimilars
  • Biotechnology
  • Chemicals
  • CLIA laboratories
  • Delivery devices
  • Diagnostic
  • Dietary supplements
  • Drug delivery
  • Drug discovery tools
  • Drug formulation
  • Laboratory instrumentation
  • Medical devices
  • Medical foods
  • MEMS technology
  • Nanotechnology
  • Oncology
  • Pharmaceuticals
  • Proteomics
  • Screening assays
  • Surgical tools
  • Therapeutics
  • Vaccines

Related Practices

Expanding Cooley's National IP Practice

We now count 45+ PhDs among our 50+ life sciences patent professionals. Together, we serve many of the world's most innovative companies. Intelligently. Read here.

IPO Handbook

Request a free copy of the IPO Handbook. Available in two versions—Emerging Companies and Life Sciences Companies, this introduction to IPOs  addresses the questions most often asked by companies contemplating public offerings.

©2003-2016 Cooley LLP and Cooley (UK) LLP. All rights reserved.
COOLEY® and the COOLEY LLP® logo are registered U.S. service marks of Cooley LLP.
Cooley was founded in 1920 – for our story, visit our timeline.